Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 10/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 10/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13632817 | 0.88 | LPAR1 (0.42) | LPAR1LPAR5OPRK1OPRM1OPRD1 | |
| SCHEMBL4364207 | 0.87 | LPAR1 (0.43) | LPAR1LPAR5OPRK1OPRM1OPRD1 | |
| SCHEMBL4015362 | 0.78 | LPAR1 (0.43) | LPAR1LPAR5 | |
| SCHEMBL4017274 | 0.77 | PPARD (0.39) | LPAR1LPAR5OPRK1OPRM1OPRD1 | |
| SCHEMBL4017318 | 0.77 | LPAR1 (0.37) | LPAR1LPAR5PARP15PARP10 | |
| SCHEMBL13633128 | 0.74 | LPAR1 (0.42) | LPAR1LPAR5LMNAHTT | |
| SCHEMBL4014189 | 0.70 | ROCK2 (0.40) | OPRK1OPRM1OPRD1ROCK2LMNA | |
| SCHEMBL3701082 | 0.70 | LPAR1 (0.47) | LPAR1LPAR5PARP15PARP10 | |
| SCHEMBL13622917 | 0.69 | MAOB (0.44) | LPAR1LPAR5HTT | |
| SCHEMBL30875454 | 0.69 | MCHR1 (0.45) | LPAR1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618996-B2 | Diaryl ether derivatives and uses thereof | PFIZER INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618996-B2 | Diaryl ether derivatives and uses thereof | PFIZER INC. (US) | 2009-11-17 | — | — | US | disclosed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | disclosed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | LPAR1 644/4885LPAR5 1129/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.